Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candi-date Malaria Vaccine (SB257049) Evaluating Schedules With or With-out Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age

Trial Profile

Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candi-date Malaria Vaccine (SB257049) Evaluating Schedules With or With-out Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Jun 2018

At a glance

  • Drugs GSK 257049 (Primary)
  • Indications Falciparum malaria
  • Focus Proof of concept; Therapeutic Use
  • Acronyms MALARIA-094
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 11 Jun 2018 Planned End Date changed from 25 Nov 2022 to 15 Dec 2022.
    • 26 Mar 2018 Planned End Date changed from 15 Dec 2022 to 25 Nov 2022 .
    • 12 Mar 2018 Planned primary completion date changed from 15 Apr 2020 to 19 Jun 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top